the company does mention in the annual report that the data package to be submitted will facilitate the development of pbt2 globally for both HD and AD programs. I'm not sure why the company would want to wait for the Hd trial to conclude before advancing another human trial for AD, if the trial failed, would that mean the AD program is finished?
I've been re-reading the Masters 2014 presentation on pbt2 data from the trials to date, and coupled with more recent results from recent screening using the Alzheimers in a dish model, it seems that the technology would have potential . it certainly has zero value right now
the company does mention in the annual report that the data...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.62M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $886 | 275.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 48 | 56368671 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 125986200 | 26 |
View Market Depth
| Last trade - 11.34am 30/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |